Receptos (NASDAQ: RCPT ) shareholders had a great day today, with the stock up 37% on exciting phase 2 data for its lead drug candidate RPC1063 in multiple sclerosis. And with a phase 3 trial pitting RPC1063 against Biogen Idec's (NASDAQ: BIIB ) Avonex ongoing, there is some exciting data ahead too.
The phase 2 trial met its primary and secondary endpoints and showed what appeared to be a pretty clean safety profile. Of course, the big question is whether Receptos can compete effectively in a multiple sclerosis market littered with heavyweights like Biogen, Novartis (NYSE: NVS ) , and Teva (NYSE: TEVA ) .
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss the trial results and why investors may want to wait for more data.
Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.